Sinovac director Wang Yu files Form 3

SINOVAC BIOTECH LTD filed an initial insider ownership report for director WANG YU (NMN) on Form 3.

Accepted by SEC EDGAR 03/18/2026 - 08:25 AM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD filed an initial insider ownership report for director WANG YU (NMN) on Form 3. This filing lists Wang as a director of the company but does not show any reported transactions or derivative positions in the provided data.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SINOVAC BIOTECH LTD (SVA) Form 3 filing report?

The Form 3 filing reports that WANG YU (NMN) is a director of SINOVAC BIOTECH LTD. It serves as an initial statement of insider status and does not show any transactions in the provided data.

Who is the reporting person in the SINOVAC BIOTECH LTD (SVA) Form 3?

The reporting person is WANG YU (NMN), identified as a director of SINOVAC BIOTECH LTD. The filing classifies this role as a director and does not list officer positions or ten percent ownership for this individual.

Does the SINOVAC BIOTECH LTD (SVA) Form 3 show any insider trades?

The provided Form 3 data shows no reported insider transactions for WANG YU (NMN). Transaction counts and share totals for buys, sells, and other activities are all zero in the transaction summary section.

Are any derivative securities disclosed in the SINOVAC BIOTECH LTD (SVA) Form 3?

The derivative section in the provided Form 3 data is empty. The derivativeSummary and derivative transaction counts are zero, indicating no listed options, warrants, or other derivative positions for WANG YU (NMN) in this filing.

Is WANG YU (NMN) a ten percent owner in SINOVAC BIOTECH LTD (SVA) according to the Form 3?

The Form 3 identifies WANG YU (NMN) as a director but not as a ten percent owner. The ten percent owner indicator is set to zero, which means this status is not reported for the individual in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WANG YU (NMN)

(Last)

(First)

(Middle)

SEE REMARKS

(Street)

BEIJING

100176

(City)

(State)

(Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

The full street address is Building 4, Floor 3, Zone 3, Yard 7, Beijing E-Town International Bio-medicine Park, Beijing Economic-Technological Development Area. Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR